首页 / 院系成果 / 成果详情页

New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment  期刊论文  

  • 编号:
    08550a10-b198-49c9-a797-fc1792354595
  • 作者:
    Sun, Yameng[1];Zhou, Jialing[1];Wang, Lin[1];Wu, Xiaoning[1];Chen, Yongpeng[2];Piao, Hongxin[3];Lu, Lungen[4];Jiang, Wei(蒋炜)[5]Xu, Youqing[6];Feng, Bo[7];Nan, Yuemin[8];Xie, Wen[9];Chen, Guofeng[10];Zheng, Huanwei[11];Li, Hai[12];Ding, Huiguo[13];Liu, Hui[14];Lv, Fudong[14];Shao, Chen[15];Wang, Tailing[15];Ou, Xiaojuan[1];Wang, Bingqiong[1];Chen, Shuyan[1];Wee, Aileen[16];Theise, Neil D.[17,18];You, Hong[1];Jia, Jidong[1];
  • 语种:
    English
  • 期刊:
    HEPATOLOGY ISSN:0270-9139 2017 年 65 卷 5 期 (1438 - 1450) ; MAY
  • 收录:
  • 摘要:

    Liver fibrosis is the net result of dynamic changes between fibrogenesis and fibrolysis. Evidence has shown that antiviral therapy can reverse liver fibrosis or even early cirrhosis caused by hepatitis B virus. However, current evaluation systems mainly focus on the severity of, but not the dynamic changes in, fibrosis. Here, we propose a new classification to evaluate the dynamic changes in the quality of fibrosis, namely: predominantly progressive (thick/broad/loose/pale septa with inflammation); predominately regressive (delicate/thin/dense/splitting septa); and indeterminate, which displayed an overall balance between progressive and regressive scarring. Then, we used this classification to evaluate 71 paired liver biopsies of chronic hepatitis B patients before and after entecavir-based therapy for 78 weeks. Progressive, indeterminate, and regressive were observed in 58%, 29%, and 13% of patients before treatment versus in 11%, 11%, and 78% after treatment. Of the 55 patients who showed predominantly regressive changes on posttreatment liver biopsy, 29 cases (53%) had fibrosis improvement of at least one Ishak stage, and, more interestingly, 25 cases (45%) had significant improvement in terms of Laennec substage, collagen percentage area, and liver stiffness despite remaining in the same Ishak stage. Conclusion: This new classification highlights the importance of assessing and identifying the dynamic changes in the quality of fibrosis, especially relevant in the era of antiviral therapy.

  • 推荐引用方式
    GB/T 7714:
    Sun Yameng,Zhou Jialing,Wang Lin, et al. New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment [J].HEPATOLOGY,2017,65(5):1438-1450.
  • APA:
    Sun Yameng,Zhou Jialing,Wang Lin,Wu Xiaoning,&Jia Jidong.(2017).New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment .HEPATOLOGY,65(5):1438-1450.
  • MLA:
    Sun Yameng, et al. "New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment" .HEPATOLOGY 65,5(2017):1438-1450.
浏览次数:6 下载次数:0
浏览次数:6
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部